Citations

Showing 10 of 108094 citations.

Letter: normalizing the ileoanal pouch—more than a one‐step technique. Authors' reply
Quinn, Kevin P. , Busciglio, Irene, Burton, Duane D. , Lee, Yong S. , Heiken, Jay P. , Sheedy, Shannon P. , Raffals, Laura E. , Busciglio, Irene A, Inoue, Akitoshi , Raffals, Laura , Fletcher, Joel G.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | June 11, 2022 | Volume: 56 | Issue: 1 | Pages: 176-177

10.1111/apt.16988 | PMID 35689327 Get It

LINKED CONTENTThis article is linked to Quinn et al papers. To view these articles, visit https://doi.org/10.1111/apt.16859 and https://doi.org/10.1111/apt.16954
Are 6-Month Functional and Isokinetic Testing Measures Risk Factors for Second Anterior Cruciate Ligament Injuries at Long-T Follow-Up?
Hale, Rena F. , Bernard, Christopher D. , Stuart, Michael J. , Hewett, Timothy E. , Krych, Aaron J. , Marigi, Erick M. , Bates, Nathaniel, Stuart, Michael J , Krych, Aaron J , Bates, Nathaniel A.

Mayo Clinic

The Journal of Knee Surgery | June 10, 2022 | Volume: 36 | Issue: 10 | Pages: 1060-1068

10.1055/s-0042-1748824 | PMID 35688443 Get It

AbstractIntroduction Second anterior cruciate ligament (SACL) injuries are a devastating complication following return to sport (RTS). Appropriate and safe RTS criteria that reduce the risk of SACL injuries are needed. The goal of this study was to investigate the relationship between functional and isokinetic testing at 6 months following primary ACL reconstruction (ACLR) as risk factors for SACL injuries.Methods Patients with primary ACLR from 1990 to 2010 were identified. Those with 6-month postoperative functional and isokinetic testing and a minimum of 2-year follow-up were included. Functional testing included vertical jump, single-leg hop, and single-leg triple hop. Isokinetic testing included concentric quadriceps and hamstrings (HSs) strength at 60 and 180 degree/s speeds. Statistical analysis evaluated the significance of the various tests between those with and without a secondary tear.Results In total, 344 patients with a mean age of 26.0 ± 9.8 years at an average time of 9.1 ± 3.5 years of follow-up were analyzed. Fifty-nine patients (17%) experienced SACL injuries at an average time of 4.8 years following ACLR with 34 (58%) ipsilateral graft ruptures and 25 (43%) contralateral tears. Several isokinetic measures were significantly different between the NO SACL and the SACL groups: quadriceps 60 degree/s limb symmetry index (LSI) (75 vs. 82% p = 0.01), HS 60 degree/s LSI (92 vs. 97%, p = 0.04), quadriceps 180 degree/s involved/body weight (BW) (41 vs. 47%, p = 0.04), and HS 180 degree/s involved/BW (30 vs. 34%, p = 0.04). Patients with involved limb peak quadriceps torque value greater than 65 or 50% of BW (60 and 180 degree/s) had a 2.2 and 3.1 times higher risk of an SACL injury.Conclusions Patients with certain elevated isokinetic scores in the injured limb at 6 months after ACLR experienced a higher rate of subsequent ACL injuries than those who had lower peak torque. Although a quantitative only analysis may not be sufficient to determine RTS criteria, clinicians should caution high-performing patients about the risk of subsequent ACL injury.Level of Evidence Cohort study; 3.
Artificial Intelligence in Oncology: Current Capabilities, Future Opportunities, and Ethical Considerations
Shreve, Jacob , Khanani, Sadia, Haddad, Tufia C. , Shreve, Jacob T, Khanani, Sadia A

Mayo Clinic

American Society of Clinical Oncology Educational Book | June 10, 2022 | Volume: No volume available | Issue: 42 | Pages: 842-851

10.1200/edbk_350652 | PMID 35687826 Get It

The promise of highly personalized oncology care using artificial intelligence (AI) technologies has been forecasted since the emergence of the field. Cumulative advances across the science are bringing this promise to realization, including refinement of machine learning– and deep learning algorithms; expansion in the depth and variety of databases, including multiomics; and the decreased cost of massively parallelized computational power. Examples of successful clinical applications of AI can be found throughout the cancer continuum and in multidisciplinary practice, with computer vision–assisted image analysis in particular having several U.S. Food and Drug Administration–approved uses. Techniques with emerging clinical utility include whole blood multicancer detection from deep sequencing, virtual biopsies, natural language processing to infer health trajectories from medical notes, and advanced clinical decision support systems that combine genomics and clinomics. Substantial issues have delayed broad adoption, with data transparency and interpretability suffering from AI’s “black box” mechanism, and intrinsic bias against underrepresented persons limiting the reproducibility of AI models and perpetuating health care disparities. Midfuture projections of AI maturation involve increasing a model’s complexity by using multimodal data elements to better approximate an organic system. Far-future positing includes living databases that accumulate all aspects of a person’s health into discrete data elements; this will fuel highly convoluted modeling that can tailor treatment selection, dose determination, surveillance modality and schedule, and more. The field of AI has had a historical dichotomy between its proponents and detractors. The successful development of recent applications, and continued investment in prospective validation that defines their impact on multilevel outcomes, has established a momentum of accelerated progress.
Cardiac resynchronization therapy outcomes with left ventricular lead concordant with latest mechanical activation: A meta‐analysis
LaPointe, Nancy M. Allen, Ali‐Ahmed, Fatima, Dalgaard, Frederik , Schmidler, Gillian Sanders , Allen LaPointe, Nancy M , Kosinski, Andrzej S. , Al‐Khatib, Sana M.

Mayo Clinic

Pacing and Clinical Electrophysiology | June 10, 2022 | Volume: 45 | Issue: 8 | Pages: 930-939

10.1111/pace.14549 | PMID 35687711 Get It

AbstractBackgroundFor cardiac resynchronization therapy (CRT), image‐guided approaches targeting left ventricular (LV) lead placement at the site of latest mechanical activation had inconsistent outcomes. We examined evidence for improved CRT outcomes when LV lead placement concordant with latest mechanical activation occurred.MethodsA review of EMBASE and PubMed was performed for randomized controlled trials or prospective observational studies from October 2008 through October 2020 comparing outcomes with concordant versus discordant LV lead placement. Meta‐analyses were performed to assess the association between concordance and death, death or heart failure (HF) hospitalization, ≥ 15% reduction in LV end systolic volume (LVESV), and changes in LVESV or ejection fraction (LVEF).ResultsFrom 5897 citations, nine publications (eight studies) with 1355 patients were selected; 975 with a concordant LV lead and 380 with a discordant lead. Mean age was 66–68 years, 82% were male, and 64% had ischemic cardiomyopathy. Meta‐analyses demonstrated a statistically significant reduction in death/HF hospitalization at 2 years (OR 0.38; 95% CI 0.16, 0.92) and LVESV at 6 months (mean difference [MD] ‐13.4%; 95% CI ‐6.7%, ‐20.0%), and an increase in LVEF (MD 4.03; 95% CI 0.77, 7.30) with the concordant LV lead. There were trends toward decreased death at 2 years (OR 0.49; 95% CI 0.19, 1.23) and ≥ 15% reduction in LVESV at 6 months (OR 3.81; 95% CI 0.24, 61.24) with concordant LV lead placement.ConclusionA concordant LV lead was associated with better CRT outcomes. Further study of feasible methods to achieve LV lead concordance is needed.
Immunomodulatory effect of different statin regimens on regulatory T-cells among patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials
Greca, Elona , Kacimi, Salah Eddine Oussama , Wireko, A A, Toufik, A, Poudel, Sujan , Prendi, B, Michel, George , Michel, J, Awuah, Wireko Andrew , Ghozy, Sherief , Toufik, A, Michel, J

Mayo Clinic

Cardiovascular Research | June 10, 2022 | Volume: 118 | Issue: Supplement_1 | Pages: No page available

10.1093/cvr/cvac066.148 Get It

Abstract Funding Acknowledgements Type of funding sources: None. Immunomodulatory effect of different statin regimens on regulatory T-cells among patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials Introduction In patients with acute coronary syndrome (ACS), studies suggest that statin therapy, besides its role in reducing the progression of atherosclerosis through its pharmacological effect, plays a pivotal role in controlling the pathogenesis of ACS through the anti-inflammatory effects of suppressor regulatory T cells (Tregs). Purpose We conducted a network meta-analysis (NMA) to determine the effects of low-dose conventional statin therapy (CST) (20 mg/day or less) and high-dose intensive statin therapy (IST) (40 mg/day or more) on the frequency of Tregs and their associated cytokines (IFN-γ, IL-10, TGF-β), compared to placebo. Methods The PubMed, Cochrane Library, and EMBASE databases were searched for randomized clinical trials (RCTs) to identify relevant articles published until June 2021. We pooled data extracted from the included studies using the standardized mean difference (SMD). A random-effects model was used to conduct this NMA. Heterogeneity was evaluated using Cochran's Q- and the I2-test. GRADE(Grading of Recommendations, Assessment, Development and Evaluations) was used to assess the study's quality. Data analysis was conducted using R software. Results A total of 505 patients were enrolled in the 5 RCTs. The NMA indicated a significant increase in Treg frequency in the CST group compared with the control group (SMD 1.77; 95% CI: 0.77 – 2.76; P-value = 0.0005) and a larger increase in the Treg frequency associated with the IST group compared with the control group (SMD 2.12; 95% CI: 1.15 – 3.10; P-value < 0.0001). However, there was significant heterogeneity and inconsistency among the included studies (τ2 = 0.6096; τ = 0.7808; I2 = 91.2% [80.5%; 96.0%]). When compared to the placebo, both CST and IST increased levels of secreted IL-10 (SMD 2.69; 95% CI: 2.07 – 3.31; P-value < 0.0001 and (SMD 2.14; 95% CI: 1.76 – 2.52; P-value < 0.0001), respectively. In comparison to the control group, CST was associated with increased levels of TGF-β (SMD 3.83; 95% CI: 0.63 – 7.0; P-value = 0.0189). This association was not seen in the IST group. IFN-γ levels decreased significantly in both the IST and CST groups (SMD -1.52; 95% CI: -1.94 – -1.10; P-value < 0.0001) and (SMD -2.34; 95% CI: -2.73 – -1.95; P-value < 0.0001) respectively. Conclusions Our study suggests that both high and low dose statin groups showed increased Treg frequency compared to the placebo group. IST showed larger benefits. Statin therapy also increased IL-10 and TGF-β cytokine levels and decreased IFN-γ levels. Therefore, statins have the potential to be the main treatment to reduce the incidence of cardiovascular events and improve cardiac function in patients with ACS through immunomodulatory effect on Treg.
Pre- and Postprocedure Imaging of Transcatheter Pulmonary Valve Implantation
Canan, Arzu , Ocazionez-Trujillo, Daniel , Vargas, Daniel , Foley, Thomas A. , Rajiah, Prabhakar , Cabalka, Allison K. , Rajiah, Prabhakar

Mayo Clinic

RadioGraphics | June 10, 2022 | Volume: 42 | Issue: 4 | Pages: 991-1011

10.1148/rg.210160 | PMID 35687519 Get It

Focal Nodular Hyperplasia and Focal Nodular Hyperplasia–like Lesions
LeGout, Jordan D. , Bolan, Candice W. , Bowman, Andrew W. , Caserta, Melanie P. , Chen, Frank K. , Cox, Kelly , Sanyal, Rupan , Toskich, Beau B. , Lewis, Jason T., Alexander, Lauren F. , Bowman, Andrew W , Alexander, Lauren F , Toskich, Beau , Lewis, Jason T.

Mayo Clinic

RadioGraphics | June 10, 2022 | Volume: 42 | Issue: 4 | Pages: 1043-1061

10.1148/rg.210156 | PMID 35687520 Get It

Clinical Testing for Tumor Cell-Free DNA: College of American Pathologists Proficiency Programs Reveal Practice Trends
Devereaux, Kelly A. , Souers, Rhona J., Merker, Jason D. , Lindeman, Neal I. , Hameed, Meera, Vasalos, Patricia, Moncur, Joel T., Lockwood, Christina M. , Xian, Rena R. , Graham, Rondell P.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | June 10, 2022 | Volume: 147 | Issue: 4 | Pages: 425-433

10.5858/arpa.2021-0585-cp | PMID 35687785 Get It

Context.— Clinical testing for tumor cell-free DNA (cfDNA) has evolved rapidly, but no practice guidelines exist. Objective.— To summarize cfDNA laboratory practices based on self-reporting and assess preanalytical, analytical, and postanalytical trends that may influence the quality, accuracy, and consistency of cfDNA testing. Design.— Data were derived from the College of American Pathologists cfDNA proficiency testing program submitted by 101 participating laboratories from 2018 to 2019. Results.— Most laboratories performing clinical circulating tumor DNA testing are commercial/nonhospital (71.2%; 72 of 101) and international (77.2%; 78 of 101) laboratories. Commercial laboratories had higher monthly test volumes than hospital-based laboratories (median, 36 versus 7–8) and tended to have larger gene panels (median, 50 versus 11 genes) when panel-based testing was offered. The main clinical indications include therapy selection and treatment/disease monitoring. Plasma is the most commonly accepted specimen, which is predominantly collected in cell-stabilizing tubes. Equal proportions of laboratories use next-generation sequencing (NGS) and non-NGS methods to assess key genes, including EGFR, BRAF, KRAS, NRAS, and IDH1. Most laboratories reported a lower limit of detection (LLOD) of 0.5%, variant allele frequency or less, which did not differ by method, NGS or non-NGS, except for EGFR. Sixty-five percent (17 of 26) of laboratories using the US Food and Drug Administration (FDA)-approved non-NGS EGFR assay report analytical sensitivities higher than 0.5%, as compared to 15% (16 of 104) of laboratories using an alternative NGS or non-NGS method. There is also a wider range in LLODs obtained for the FDA-approved EGFR assay than nonapproved assays. Conclusions.— These results highlight emerging practice trends and serve as a foundation to initiate future practice recommendations.
ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer
Hsieh, Cheng‐En , Krishnan, Sunil , Wu, Ren‐Chin , Boda, Akash R. , Liu, Arthur , Winkler, Michelle , Hsu, Wen‐Hao , Lin, Steven H. , Hung, Mien‐Chie , Bhanu, Krithikaa Rajkumar , Srinivasamani, Anupallavi, Azevedo, Ricardo , Chou, Yung‐Chih , DePinho, Ronald A. , Gubin, Matthew M. , Slay, Ravaen, Hegde, Shweta , Hartley, Genevieve , Lea, Spencer T. , Prasad, Rishika , Morrow, Brittany, Couillault, Coline , Steiner, Madeline , Wang, Chun‐Chieh, Venkatesulu, Bhanu Prasad , Curran, Michael A. , Hsieh, Rodney Cheng-En , Lin, Steven H , Chan, Li-Chuan , De Azevedo, Ricardo Alexandre , Chou, Yung-Chih , DePinho, Ronald A , Gubin, Matthew , Vilar, Eduardo , Chen, Chao Hsien , Jayaprakash, Priyamvada , Lea, Spencer T , Prasad, Rishika , Couillault, Coline Agnes , Wang, Chun-Chieh , Taniguchi, Cullen , Kim, Betty Y S , Chen, Junjie , Rudqvist, Nils-Petter , Curran, Michael A , Krishnan, Sunil , Liu, Arthur J , Kim, Betty Y.S. , Chen, Junjie

Mayo Clinic

Science Immunology | June 10, 2022 | Volume: 7 | Issue: 72 | Pages: No page available

10.1126/sciimmunol.abl9330 | PMID 35687697 Get It

Radiotherapy (RT) of colorectal cancer (CRC) can prime adaptive immunity against tumor-associated antigen (TAA)–expressing CRC cells systemically. However, abscopal tumor remissions are extremely rare, and the postirradiation immune escape mechanisms in CRC remain elusive. Here, we found that irradiated CRC cells used ATR-mediated DNA repair signaling pathway to up-regulate both CD47 and PD-L1, which through engagement of SIRPα and PD-1, respectively, prevented phagocytosis by antigen-presenting cells and thereby limited TAA cross-presentation and innate immune activation. This postirradiation CD47 and PD-L1 up-regulation was observed across various human solid tumor cells. Concordantly, rectal cancer patients with poor responses to neoadjuvant RT exhibited significantly elevated postirradiation CD47 levels. The combination of RT, anti-SIRPα, and anti–PD-1 reversed adaptive immune resistance and drove efficient TAA cross-presentation, resulting in robust TAA-specific CD8 T cell priming, functional activation of T effectors, and increased T cell clonality and clonal diversity. We observed significantly higher complete response rates to RT/anti-SIRPα/anti–PD-1 in both irradiated and abscopal tumors and prolonged survival in three distinct murine CRC models, including a cecal orthotopic model. The efficacy of triple combination therapy was STING dependent as knockout animals lost most benefit of adding anti-SIRPα and anti–PD-1 to RT. Despite activation across the myeloid stroma, the enhanced dendritic cell function accounts for most improvements in CD8 T cell priming. These data suggest ATR-mediated CD47 and PD-L1 up-regulation as a key mechanism restraining radiation-induced immune priming. RT combined with SIRPα and PD-1 blockade promotes robust antitumor immune priming, leading to systemic tumor regressions.
Characterization of primary cutaneous T‐cell lymphoma following solid organ transplantation
Shimshak, Serena , Dai, Christina , Comfere, Nneka I. , Sokumbi, Olayemi , Shimshak, Serena J E

Mayo Clinic

International Journal of Dermatology | June 10, 2022 | Volume: 62 | Issue: 4 | Pages: 494-500

10.1111/ijd.16300 | PMID 35687656 Get It

Abstract Background Immunosuppression following solid organ transplantation is a known risk factor for the development of posttransplant lymphoproliferative disorders (PTLD). Primary cutaneous T‐cell lymphoma (CTCL) occurring in the posttransplant setting is rare, which has made comprehensive understanding of this disease challenging. This study aims to further characterize the spectrum of clinicopathologic features of CTCL in solid organ transplant recipients (SOTR). Methods A retrospective chart review was performed for SOTR who were diagnosed with CTCL at a multi‐site academic medical center from January 1, 1998, to December 31, 2013. Eight patients fulfilled the inclusion criteria and were included in this study. Data collected included patient demographics, transplanted organ, the time between transplant and CTCL diagnosis, clinical presentation and rash morphology, a histological subtype of CTCL, immunosuppression regimens, and patient status. Twelve diagnostic skin biopsies for five patients were examined and reviewed by a board‐certified dermatopathologist. Results Six (75%) out of the eight patients were men, two (25%) were women, and the median age was 53 years. The median time from the date of transplant to the diagnosis of CTCL was 8.2 years. Transplanted organs included the liver (4), kidney (3), and heart (1). Clinical presentation varied from papulonodules, comedone‐like lesions, intense pruritis, and scaly erythematous eruptions. The most common histologic presentation was folliculotropic mycosis fungoides (FMF) (7/12). Epstein–Barr virus‐in situ hybridization (EBV‐ISH) was negative in all specimens. Conclusions We emphasize the rarity of CTCL among SOTR. Although rare in the general population, the FMF subtype appears to be disproportionately seen in SOTR compared with other CTCL.